These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 20067769)

  • 21. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
    Nguyen D; Zajac-Kaye M; Rubinstein L; Voeller D; Tomaszewski JE; Kummar S; Chen AP; Pommier Y; Doroshow JH; Yang SX
    Cell Cycle; 2011 Dec; 10(23):4074-82. PubMed ID: 22101337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The antitumor triazoloacridone C-1305 is a topoisomerase II poison with unusual properties.
    Lemke K; Poindessous V; Skladanowski A; Larsen AK
    Mol Pharmacol; 2004 Oct; 66(4):1035-42. PubMed ID: 15258255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PARP-1 inhibition induces a late increase in the level of reactive oxygen species in cells after ionizing radiation.
    Cieślar-Pobuda A; Saenko Y; Rzeszowska-Wolny J
    Mutat Res; 2012 Apr; 732(1-2):9-15. PubMed ID: 22321899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles.
    Muñoz-Gámez JA; López Viota J; Barrientos A; Carazo Á; Sanjuán-Nuñez L; Quiles-Perez R; Muñoz-de-Rueda P; Delgado Á; Ruiz-Extremera Á; Salmerón J
    Liver Int; 2015 Apr; 35(4):1430-41. PubMed ID: 24821649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage.
    Boulton S; Kyle S; Durkacz BW
    Carcinogenesis; 1999 Feb; 20(2):199-203. PubMed ID: 10069454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Major contribution of the multidrug transporter P-glycoprotein to reduced susceptibility of poly(ADP-ribose) polymerase-1 knock-out cells to doxorubicin action.
    Wesierska-Gadek J
    J Cell Biochem; 2005 Aug; 95(5):1012-28. PubMed ID: 15861398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells.
    Tentori L; Portarena I; Bonmassar E; Graziani G
    Cell Death Differ; 2001 May; 8(5):457-69. PubMed ID: 11423906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis.
    Muñoz-Gámez JA; Martín-Oliva D; Aguilar-Quesada R; Cañuelo A; Nuñez MI; Valenzuela MT; Ruiz de Almodóvar JM; De Murcia G; Oliver FJ
    Biochem J; 2005 Feb; 386(Pt 1):119-25. PubMed ID: 15456408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity.
    Preet R; Mohapatra P; Mohanty S; Sahu SK; Choudhuri T; Wyatt MD; Kundu CN
    Int J Cancer; 2012 Apr; 130(7):1660-70. PubMed ID: 21544805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitotic functions of poly(ADP-ribose) polymerases.
    Slade D
    Biochem Pharmacol; 2019 Sep; 167():33-43. PubMed ID: 30910692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
    Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
    J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mitotic bypass via an occult cell cycle phase following DNA topoisomerase II inhibition in p53 functional human tumor cells.
    Smith PJ; Marquez N; Wiltshire M; Chappell S; Njoh K; Campbell L; Khan IA; Silvestre O; Errington RJ
    Cell Cycle; 2007 Aug; 6(16):2071-81. PubMed ID: 17721081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defective control of mitotic and post-mitotic checkpoints in poly(ADP-ribose) polymerase-1(-/-) fibroblasts after mitotic spindle disruption.
    Halappanavar SS; Shah GM
    Cell Cycle; 2004 Mar; 3(3):335-42. PubMed ID: 14726664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. G2 arrest in response to topoisomerase II inhibitors: the role of p53.
    Clifford B; Beljin M; Stark GR; Taylor WR
    Cancer Res; 2003 Jul; 63(14):4074-81. PubMed ID: 12874009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
    Delaney CA; Wang LZ; Kyle S; White AW; Calvert AH; Curtin NJ; Durkacz BW; Hostomsky Z; Newell DR
    Clin Cancer Res; 2000 Jul; 6(7):2860-7. PubMed ID: 10914735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Poly(ADP-ribose) polymerase-1 is a positive regulator of the p53-mediated G1 arrest response following ionizing radiation.
    Wieler S; Gagné JP; Vaziri H; Poirier GG; Benchimol S
    J Biol Chem; 2003 May; 278(21):18914-21. PubMed ID: 12642583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Poly(ADP-RIBOSE) polymerase-1 (Parp-1) antagonizes topoisomerase I-dependent recombination stimulation by P53.
    Baumann C; Boehden GS; Bürkle A; Wiesmüller L
    Nucleic Acids Res; 2006; 34(3):1036-49. PubMed ID: 16473854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity.
    Kuo ML; Shen SC; Yang CH; Chuang SE; Cheng AL; Huang TS
    Oncogene; 1998 Oct; 17(17):2225-34. PubMed ID: 9811453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe.
    Castedo M; Perfettini JL; Roumier T; Yakushijin K; Horne D; Medema R; Kroemer G
    Oncogene; 2004 May; 23(25):4353-61. PubMed ID: 15048074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation.
    Kaundal RK; Shah KK; Sharma SS
    Life Sci; 2006 Nov; 79(24):2293-302. PubMed ID: 16935310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.